Values as of: 2024-09-24
COMMON STOCK | Biotechnology |
Last Closing
USD 0.095Change
0.00 (0.00)%Market Cap
USD 8.28MVolume
0.01MAnalyst Target
N/AVerdict
Verdict
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Company Website : https://hemostemix.com
Currency: CAD
Country : Canada
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| NGEN:CA | NervGen Pharma Corp |
+0.02 (+0.79%) |
USD 0.19B |
| ARCH:CA | Arch Biopartners Inc |
+0.01 (+0.61%) |
USD 0.11B |
| COV:CA | Covalon Technologies Ltd. |
+0.04 (+1.09%) |
USD 0.08B |
| MIR:CA | MedMira Inc |
-0.01 (-11.11%) |
USD 0.06B |
| NRX:CA | NurExone Biologic Inc. |
+0.01 (+1.79%) |
USD 0.04B |
| TTI:CA | Thiogenesis Therapeutics Corp. |
N/A |
USD 0.03B |
| GSD:CA | Devonian Health Group Inc |
N/A |
USD 0.02B |
| KNE:CA | Kane Biotech Inc |
-0.01 (-7.14%) |
USD 0.02B |
| SBM:CA | Sirona Biochem Corp |
-0.01 (-14.29%) |
USD 0.02B |
| RKV:CA | Rakovina Therapeutics Inc |
N/A |
USD 7.22M |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 35.71% | 56% | F | 73% | C | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 35.71% | 56% | F | 73% | C | ||
| Trailing 12 Months | |||||||
| Capital Gain | -17.39% | 35% | F | 49% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -17.39% | 35% | F | 49% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -84.17% | 18% | F | 9% | A- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -84.17% | 18% | F | 9% | A- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -1.83% | 50% | F | 47% | F | ||
| Dividend Return | -1.83% | 50% | F | 47% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 106.15% | 17% | F | 28% | F | ||
| Risk Adjusted Return | -1.72% | 50% | F | 48% | F | ||
| Market Capitalization | 8.28M | 50% | F | 50% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
